Developing a long-acting treatment for HIV
Official title: IND-enabling studies for eCD4-Ig as a long-acting recombinant protein therapeutic
Funded at Emmune, INC · NIH-11183602 · Data updated 2026-11-12
This study is working on a new treatment for HIV that uses a special protein to help your body fight the virus, and it aims to make it easy to take with just a shot every three months.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emmune, INC NIH-funded |
| Lab location | 1 site (Juno Beach, UNITED STATES) |
| Project start | May 9, 2025 |
| Project end | October 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $300,000 |
| NIH project number | 1R43AI191927-01 |
| Project ID | NIH-11183602 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with HIV who are seeking new treatment options.
✕Less likely to help
Patients who are not infected with HIV or those who are not eligible for new therapeutic interventions may not benefit from this research.
What this research studies
This research focuses on creating a new therapeutic protein called eCD4-Ig, which targets HIV by mimicking parts of the virus's receptors. The goal is to enable a long-acting treatment that can be administered every three months through a simple injection. Before testing in humans, the research will conduct necessary laboratory studies to ensure safety and effectiveness. This includes assessing how the treatment interacts with human immune cells and conducting toxicity studies in animal models.
Why it matters
Potential benefit: If successful, this research could provide a long-lasting and effective treatment option for individuals living with HIV.
How similar studies have gone: Previous research has shown promise in developing antibody-like therapeutics for HIV, indicating that this approach could be viable.
Where this research is happening
-
Emmune, INC
Juno Beach, United States Active
Researchers
- Principal investigator: Alpert, Michael David — Emmune, INC
- Study coordinator: Alpert, Michael David
Related research
Other NIH-funded projects on the same topics.
-
Non-viral gene therapy to treat and prevent atherosclerosis (for patients)
A small biotechnology study is testing a non-viral DNA delivery method using lipid nanoparticles to help prevent and treat atherosclerosis in adults.
-
Making eCD4-Ig, a long‑acting HIV medicine
Developing ways to manufacture eCD4-Ig, a long‑lasting antibody‑like medicine that could help people living with or at risk for HIV.
-
Long-acting eCD4-Ig therapy for HIV prevention and treatment
A FastTrack SBIR grant funds early non-human and IND-enabling tests to develop a long-acting eCD4-Ig protein that could be given every three months to help prevent or treat HIV.
-
Developing a one-time gene therapy to suppress HIV replication.
This study is testing a new type of gene therapy that uses a special protein to help keep HIV under control with just one shot in the muscle, so people living with HIV might not need to take daily medications anymore.
-
Modified COVID-19 booster focused on the virus's receptor-binding domain
Testing a new COVID-19 booster that uses a modified piece of the virus's spike protein to steer immune protection toward parts that neutralize variants.
-
Developing targeted vaccines for COVID-19 variants
This study is testing a new type of booster vaccine designed to help people who have already been vaccinated against COVID-19 by making it better at fighting off different variants of the virus.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.